PKI-179

DB13109InvestigationalSmall molecule

PKI-179 has been used in trials studying the treatment of Advanced Malignant Solid Tumors.

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and Serine/threonine-protein kinase mTOR
Curator reviewed
Formula / weight: C₂₅H₂₈N₈O₃ · 488.552 g/mol (avg)
Code names: PKI-179

Resolves to

Compound

Structure

InChIKeyWXUUCRLKXQMWRY-OYRHEFFESA-NSMILESO=C(NC1=CC=NC=C1)NC1=CC=C(C=C1)C1=NC(=NC(=N1)N1[C@H]2CC[C@@H]1COC2)N1CCOCC1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with PKI-179, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.